FL-treated B cells on SGs by co-culture of these circulating B cells with human SG (HSG) epithelial cell line cells.

Results (1) There were more serum FL in SS patients than in HCs (135.8 ± 5.5 vs 64.4 ± 4.5 pg/ml, $p < 0.001$), their levels correlated with the clinical activity of the disease and with the proportions of Bm2/Bm2' in the PB ($r = 50$, $p < 0.001$). (2) Furthermore, Flt3 was selectively expressed in these circulating B cell subsets. With regard to the SGs, B cells expressed Flt3, while epithelial cells produced FL. (3) Finally, co-cultures revealed that FL potentiated the B cell receptor-induced proliferation of B lymphocytes, and the HSG-mediated survival of B cells was abrogated by anti-FL and/or anti-Flt3 antibodies.

Conclusion The pSS patients increase their serum levels of FL, relative to the excess of Bm2/Bm2' in their PB. By supporting the proliferation of B cells, FL favours the development of B cell lymphoma in SS.

A35 SJÖGREN'S SYNDROME (SS): ARE INCREASED SERUM LEVELS OF CYTOKINE FMS-LIKE TYROSINE KINASE 3 LIGAND (FLT3L) INDICATIVE OF LYMPHOMA?

G J Tobón, V Devauchelle, P Youinou, J-O Pers EA 2216 'Immunologie et Pathologie' and IFR 148 ScInBioS, Université de Brest, and Université Européenne de Bretagne, Brest, France

10.1136/ard.2010.129585i

Background Flt3L, which is involved in the ontogenesis of B cells (particularly in their malignant proliferation in pSS) might contribute to the absolute excess of activated Bm2/germinal centre founder Bm2' B lymphocytes which characterises the peripheral blood (PB) pattern of these patients.

Objectives Our aims were threefold: (1) Compare the serum levels of FL of 64 Sjögren's syndrome (SS) patients with those of 20 healthy controls (HCs). (2) Quantify B cell expression of this ligand and its receptor Flt3 in the PB and the salivary glands (SGs) of patients. (3) And evaluate the effect of